TP53 Gene Function
Tumor Protein P53
Overview
TP53 is the most frequently mutated gene in human cancer (>50% of all tumours). Missense hotspot mutations (R175H, R248W, G245S, R273H) eliminate p53 tumour suppressive function, exert dominant-negative effects over remaining wild-type p53 tetramers, and confer gain-of-function oncogenic properties — STAT pathway co-activation, chromatin remodelling, metabolic reprogramming, and enhanced metastatic capacity. MDM2 inhibitors (idasanutlin, navtemadlin) can only restore p53 activity in TP53-wild-type tumours that suppress p53 through MDM2 amplification; they have no role in TP53-mutant disease. Restoring function to missense-mutant p53 remains one of the central unsolved challenges of cancer drug development.
Molecular Mechanism
Mechanism Summary
TP53 is altered in roughly half of human cancers, commonly disabling p53-mediated checkpoint, apoptotic and senescence programmes. Many missense hotspot variants produce a stable, dysfunctional protein; some can inhibit remaining wild-type p53 through a dominant-negative effect, while experimentally reported gain-of-function phenotypes vary by variant and biological context. MDM2 inhibitors depend on functional wild-type p53 and therefore address a different biological category from most TP53-mutant disease.
Step-by-Step Mechanism
DNA double-strand breaks (DSBs) are sensed by the MRN complex (MRE11–RAD50–NBS1), which recruits and activates ATM kinase at the break site.
MDM2 dissociation prevents p53 ubiquitination and proteasomal degradation. Concurrent p300/CBP-mediated acetylation at Lys382 enhances p53 transcriptional activity.
Stabilised p53 tetramerises and binds p53-response elements in target gene promoters, transcriptionally activating CDKN1A (encoding p21), which inhibits CDK2/cyclin E to impose G1/S arrest.
If DNA damage is irreparable, p53 transactivates pro-apoptotic targets BAX, PUMA (BBC3), and NOXA (PMAIP1). These BH3-only proteins displace BCL2/BCL-XL, enabling BAX/BAK oligomerisation and mitochondrial outer membrane permeabilisation.
Cytochrome c released from mitochondria associates with APAF1 and caspase-9 to form the apoptosome, activating effector caspase-3 and -7 for irreversible apoptotic execution.
p53 simultaneously transcribes MDM2, establishing a negative feedback loop that limits p53 activity once repair is complete and the stress signal dissipates.
Upstream Regulators
Phosphorylates p53 Ser15 in response to DSBs, disrupting MDM2 interaction
Phosphorylates p53 Ser15 in response to replication stress and single-stranded DNA
Sequesters MDM2 in the nucleolus under oncogenic stress, stabilising p53 independent of DNA damage
Downstream Targets
CDK2/CDK4 inhibition → G1/S arrest
Pro-apoptotic BAX/BAK activation → mitochondrial permeabilisation
Negative feedback loop terminating p53 activity
G2/M checkpoint enforcement; nucleotide excision repair
Metabolic reprogramming; reduction of ROS to allow repair
Key Post-Translational Modifications
Disrupts MDM2 binding; primary stabilisation signal
Secondary MDM2 disruption; reinforces stability
Enhances sequence-specific DNA binding and transcriptional activation
Disease Mechanism
TP53 alterations can let cells bypass DNA-damage checkpoints, tolerate oncogenic stress and evade apoptosis, accelerating tumour evolution. Many cancer-associated variants are missense substitutions, but their consequences are not interchangeable: loss of transcriptional function is common, dominant-negative activity depends partly on retained oligomerisation and the presence of wild-type p53, and proposed gain-of-function phenotypes can be variant- and context-dependent. No approved therapy broadly restores diverse missense-mutant p53 proteins. MDM2 inhibitors require functional wild-type p53 and are generally not expected to rescue a structurally dysfunctional mutant. Some mutant-p53 models show additional invasion, transcriptional or immune effects, but a hotspot label alone is not enough to infer those phenotypes in a patient. Pathogenic germline TP53 variants cause Li-Fraumeni syndrome; cancer risk and surveillance require specialist interpretation because they vary by sex, age, variant and family context.
Database References
Key Pathways
- ·DNA damage response
- ·Apoptosis
- ·Cell cycle arrest
- ·p53 signaling pathway
- ·Cellular senescence
- ·Oncogene-induced senescence
Disease Associations
- ·Li-Fraumeni syndrome
- ·Lung, colorectal, breast, ovarian cancers
- ·Adrenocortical carcinoma
- ·Sarcoma
Research Activity
TP53 is an actively studied target: about 100+ clinical trials that mention it are currently recruiting on ClinicalTrials.gov. Trial activity reflects research interest, not proven benefit — designs, endpoints and populations vary widely.
Track TP53 trials
New and changed oncology trials, summarised in plain language each day.
Functional Partners
Common Questions About TP53
What does TP53 do?
TP53 encodes p53, a transcription factor that acts as the genome's central stress sensor. When DNA is damaged, p53 halts the cell cycle at the G1/S checkpoint via transcriptional activation of p21 (CDKN1A), buying time for repair. If damage is irreparable, p53 shifts its programme toward apoptosis by upregulating BAX, PUMA, and NOXA.
Is TP53 a tumor suppressor gene or oncogene?
TP53 is a tumor suppressor gene — it is loss of function, not gain of function, that drives cancer. Wild-type p53 actively blocks tumour development; the more than 50% of cancers that carry TP53 mutations lose this brake, allowing genomic instability to accumulate unchecked.
What happens when TP53 is mutated in cancer?
Cells lacking functional p53 fail to arrest the cell cycle after DNA damage, permitting mutations to accumulate and propagate. TP53 mutations are found in over 50% of all human cancers and are strongly associated with genomic instability, chemotherapy resistance, and poor prognosis.
What is Li-Fraumeni syndrome?
Li-Fraumeni syndrome is a hereditary cancer-predisposition disorder caused by pathogenic germline TP53 variants. An NCI cohort reported cumulative cancer incidence approaching 100% by age 70, but risk varies by sex, age, variant, and cancer type. Associated cancers include sarcomas, breast cancers, brain tumours, and adrenocortical carcinomas, often at unusually young ages.
Why is TP53 called the guardian of the genome?
The phrase reflects p53's role as the hub integrating signals from DNA double-strand breaks (via ATM), oncogene activation (via ARF), and hypoxia (via HIF1A), then deciding whether to arrest, repair, senesce, or eliminate the affected cell. No other single protein controls so many cancer-relevant decisions.
What are gain-of-function TP53 mutations and what oncogenic properties do they confer?
Gain-of-function (GOF) TP53 mutations — primarily at hotspots R175H, R248W, R248Q, R273H, and R282W — not only lose tumour suppressive activity but acquire new oncogenic properties absent from wild-type p53. GOF p53 proteins: (1) co-activate oncogenic transcription factors (STAT3, ETS2, c-Jun) that wild-type p53 would normally suppress; (2) bind and inactivate p63 and p73, paralogues that compensate for p53 loss in apoptosis; (3) remodel chromatin at novel gene loci promoting invasion and metastasis; (4) are metabolically more stable than wild-type p53, accumulating to high levels (explaining the strong IHC staining of TP53-mutant tumours). GOF mutations are associated with worse prognosis and greater chemotherapy resistance than simple TP53 null mutations, suggesting the mutant protein actively drives malignancy rather than merely losing tumour suppression.
Why can MDM2 inhibitors not treat TP53-mutant cancer, and in which patients do they work?
MDM2 inhibitors (idasanutlin, navtemadlin, milademetan) work by occupying the p53-binding pocket of MDM2, blocking MDM2-mediated p53 ubiquitination and allowing p53 to accumulate and activate. This mechanism requires functional, wild-type p53 protein — if p53 is structurally damaged by a missense mutation, blocking MDM2 simply allows a non-functional p53 to accumulate without therapeutic benefit and may even be harmful by occupying the remaining p53 signalling machinery. MDM2 inhibitors are therefore selective for TP53 wild-type tumours that overexpress MDM2 — predominantly well-differentiated and dedifferentiated liposarcomas (>90% MDM2 amplification) and a subset of AML and other haematological malignancies. TP53 mutation status must be confirmed before prescribing these agents.